This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Markers			
DNA methylation signatures in chronic lymphocytic leukemia (CLL)	<p>DNA methylation signatures could help identify CLL subtypes and improve disease prognosis. In samples from 139 patients, epigenomic analysis revealed differences in CpG methylation patterns between naïve B cell-like and memory B cell-like CLLs and also identified a third subtype that is an intermediate between the molecular subtypes. In the patients, 20% of those with memory B cell-like disease, 43% of those with the intermediate disease phenotype and 100% of those with naïve B cell-like disease required treatment at 10 years. Next steps include validating the methylation signatures in additional patient cohorts.</p> <p>SciBX 5(42); doi:10.1038/scibx.2012.1125 Published online Oct. 25, 2012</p>	<p>Patent application filed covering use in CLL; available for licensing from the Innovation Department at the Fundacio Clinic for Biomedical Research</p>	<p>Kulis, M. <i>et al. Nat. Genet.</i>; published online Oct. 14, 2012; doi:10.1038/ng.2443 Contact: José I. Martin-Subero, University of Barcelona, Barcelona, Spain e-mail: imartins@clinic.ub.es</p>